

## Different effects of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin and Aroclor 1254 on thyroxine metabolism and transport

**Lans, Martine C., Brouwer, I., de Winden, P. and Brouwer A.**

Department of Toxicology, Agricultural University Wageningen, Tuinlaan 5, 6703 HE Wageningen, The Netherlands.

### **Abstract**

2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) and AROCLOR 1254 exposure to rats decreased plasma thyroxine (T<sub>4</sub>) levels and induced thyroxine glucuronidation (T<sub>4</sub>-UGT). In AROCLOR 1254 treated rats both T<sub>4</sub>-UGT induction and selective inhibition of plasma T<sub>4</sub> transport by transthyretin (TTR) were observed. This may be due to the presence of hydroxylated metabolites in plasma of especially AROCLOR 1254 but not TCDD-treated rats.

### **Introduction**

PCBs, PCDDs and PCDFs can exhibit a common biological toxic response mediated by Ah-receptor binding, like thymic atrophy, hepatotoxicity, chloracne, induction of liver cytochrome P450 1A1 and EROD activity<sup>1</sup>. Concurrently, thyroid hormone levels and metabolism are changed after exposure to 3,3',4,4'-tetrachlorobiphenyl<sup>2</sup> (CB 77), 3,3',4,4',5,5'-hexachlorobiphenyl<sup>3</sup> (CB 169), AROCLOR 1254<sup>4</sup> and TCDD<sup>5,6</sup>. Induction of thyroxine (T<sub>4</sub>) glucuronidation (T<sub>4</sub>-UGT) and increased biliary clearance of T<sub>4</sub> has been suggested as the main cause of plasma T<sub>4</sub> depletion by TCDD and related compounds. Another mechanism involved in decreasing T<sub>4</sub> levels was found for easily metabolisable PCBs, such as CB 77<sup>7</sup>. Hydroxylated metabolites of these compounds, like 4-OH-3,3',4',5-tetrachlorobiphenyl, a metabolite of CB 77, showed specific inhibition of T<sub>4</sub> binding to transthyretin (TTR)<sup>7</sup>, the major T<sub>4</sub> transport protein in rodents, causing T<sub>4</sub> levels to drop.

The aim of the present studies was to determine the contribution of both mechanisms (i.e. increased T<sub>4</sub> glucuronidation and TTR-T<sub>4</sub> binding inhibition) to the decrease of plasma T<sub>4</sub> levels of rats exposed to 2,3,7,8-TCDD or AROCLOR 1254.

## Materials and methods

### Experiment 1

8 Female Wistar rats (18-20 weeks) were treated with 25 µg 2,3,7,8-TCDD/kg b.w. (TCDD) or cornoil (CON). After 4 days four CON or TCDD rats were treated with  $^{125}\text{I-T}_4$  (10-15 µCi), bloodsamples were taken after 3,6 and 24 hours. On day 5 these rats and the 4 CON or TCDD rats not treated with  $^{125}\text{I-T}_4$ , were killed and organs/tissues were removed and stored at -80°C.

### Experiment 2

14 Female Wistar rats (18-20 weeks) were treated with 50 mg AROCLOR 1254/kg b.w.(ARO50), 500 mg AROCLOR 1254/kg b.w. (ARO500) or cornoil (CON). After 2 and 7 days 3 animals of each group were treated with  $^{125}\text{I-T}_4$  (10-15 µCi), bloodsamples were taken after 3,6 and 24 hours. On day 3 and 8 these animals and 4 ARO50, ARO500 and CON rats not treated with  $^{125}\text{I-T}_4$  were killed and organs/tissues were removed and stored at -80°C.

### Biochemical parameters

EROD-activity was measured according to Lubet et al.<sup>9</sup>.  $\text{T}_4$  levels were measured using a chemoluminescence immunoassay (Amersham, Amersham).  $\text{T}_4$  glucuronidation was measured by the method as described by Beetstra et al.<sup>10</sup> (1991).  $^{125}\text{I-T}_4$  binding to TTR in plasma was determined by PAGE-gelelectroforese and counting radioactivity of the separated  $^{125}\text{I-T}_4$ -binding proteins: albumin and TTR.

## Results

The plasma  $\text{T}_4$  levels and binding and hepatic EROD and  $\text{T}_4$ -UGT results are listed in Table 1. All exposed groups, except the ARO50 group, showed a marked decrease in plasma total  $\text{T}_4$  levels. EROD activity was significantly induced by TCDD and ARO50 and ARO500 treatment (resp. 170, 11 and 58 times induced). Simultaneously,  $\text{T}_4$ -UGT activity was increased for both low ARO50 and high dosed ARO500 groups after 3 or 8 days and significantly induced by TCDD after 4 days. However, due to large interindividual variation the  $\text{T}_4$ -UGT activity in AROCLOR rats was not significantly increased. Specific binding of  $^{125}\text{I-T}_4$  to TTR or albumin in sera of TCDD or ARO500 exposed rats was decreased. In ARO500 rats a drastic decrease in the ratios of specific  $^{125}\text{I-T}_4$  binding to TTR vs. albumin was found immediately at 3,6, and 24 hours after  $^{125}\text{I-T}_4$  exposure, while in TCDD exposed rats, the ratio of  $^{125}\text{I-T}_4$  binding to TTR vs. albumin was normal at 3 hours but decreasing at 6 and 24 hours after  $^{125}\text{I-T}_4$  exposure.

## Discussion

Exposure of rats to TCDD or low or high doses of AROCLOR 1254, led to decreases in plasma total  $\text{T}_4$  levels, as earlier described by Bastomsky<sup>4,6</sup>, Brouwer<sup>7</sup> and Lans<sup>5</sup>. Concomitantly,  $\text{T}_4$ -UGT activity was induced in tandem with EROD-activity in both TCDD and low and high AROCLOR 1254 treated groups. Ratios of  $^{125}\text{I-T}_4$  binding to TTR vs. albumin, used as indicators of selective displacement of  $\text{T}_4$  from TTR<sup>7</sup>, were reduced especially in high dosed AROCLOR 1254 rats and less in TCDD treated animals. This reduction in  $^{125}\text{I-T}_4$  binding ratios indicate the presence of hydroxylated metabolites in AROCLOR 1254 treated rats. Klasson-Wehler<sup>11</sup> showed the presence of

Table 1 Effects of 2,3,7,8-TCDD and low and high dose AROCLOR 1254 exposure on plasma  $T_4$  levels, EROD activity,  $T_4$ -glucuronidation and specific binding of  $^{125}I$ - $T_4$  to TTR and albumin. Ratios of  $^{125}I$ - $T_4$  binding to TTR over albumin are given at T=3,6 and 24 hours after  $^{125}I$ - $T_4$  exposure. Results shown are means  $\pm$  S.D. of tri- or quadruplicate measurements. Significant differences (Student's t-Test): \*P < 0.05

Group	Plasma $TT_4$ (nM)	EROD-act nmol/min/mg	$T_4$ -UGT pmol/min/mg	$T_4$ -binding TTR/alb (3h)	$T_4$ -binding TTR/alb (6h)	$T_4$ -binding TTR/alb (24 h)
Control Exp.1	34.9 $\pm$ 8.2	0.020 $\pm$ 0.003	1.73 $\pm$ 0.13	4.2	3.9	4.6
TCDD	18.7 $\pm$ 1.1*	3.390 $\pm$ 0.731*	6.78 $\pm$ 1.17*	4.4	3.1	2.5
Control Exp.2	29.3 $\pm$ 3.7	0.039 $\pm$ 0.007	2.39 $\pm$ 0.85	4.1	3.7	8.0
ARO50 day 3	32.9 $\pm$ 6.0	0.469 $\pm$ 0.461	3.34 $\pm$ 1.62	4.4	3.8	3.8
ARO500 day 3	12.9 $\pm$ 11.9*	2.336 $\pm$ 1.026*	6.84 $\pm$ 2.34	2.7	1.7	2.3
ARO50 day 8	31.2 $\pm$ 7.9	0.345 $\pm$ 0.344	2.55 $\pm$ 1.34	4.1	3.6	4.2
ARO500 day 8	10.1 $\pm$ 5.2*	2.288 $\pm$ 0.799*	11.80 $\pm$ 8.23	1.5	1.2	1.6

significant amounts of hydroxylated metabolites of PCBs in plasma of environmentally exposed seal, polar bear and man. The major metabolite present in these plasma samples, 4-OH-2,3,3',4',5-pentachlorobiphenyl (4-OH-PeCB), has high affinity for the TTR protein<sup>7</sup>. In addition this metabolite is found in plasma of rats exposed to AROCLOR 1254<sup>11</sup>. Some hydroxylated PCB-metabolites are capable of inhibiting TTR- $T_4$  binding as was found in vitro<sup>8</sup>, requiring a meta- or para hydroxylation with adjacent halogen substitution(s).

TCDD treated animals also showed some reduction in  $^{125}I$ - $T_4$  binding ratios. Hydroxy-metabolites of TCDD do have a similar high affinity for  $T_4$  binding site on TTR as the 4-OH-PeCB. However, analysis of rat plasma did not show any presence of OH-metabolites of TCDD<sup>12</sup>.

# TOX

In conclusion, plasma  $T_4$  reduction by TCDD is mainly caused by  $T_4$ -UGT induction, while both  $T_4$ -UGT induction and  $T_4$  displacement from TTR by OH-PCBs may be involved in  $T_4$  reduction by AROCLOR 1254 and other PCB mixtures.

## References

- 1 McConnell, E.E. Acute and chronic toxicity, carcinogenesis, reproduction, teratogenesis and mutagenesis in animals. In: *Halogenated biphenyls, terphenyls, naphthalenes, dibenzodioxins and related products* (Ed. R.D. Kimbrough), Elsevier/North Holland, 1980:109-150.
- 2 Brouwer, A., van den Berg, K.J. Binding of a metabolite of 3,4,3',4'-tetrachlorobiphenyl to transthyretin reduces serum vitamin A transport by inhibiting the formation of the protein complex carrying both retinol and thyroxine. *Toxicol. Appl. Pharmacol.* 1986;85:301-312.
- 3 Morse, D.C., Groen, D., Veerman, M., Van Amerongen, C.J., Koeter, H.B.W.M., Smits van Prooijje, A.E., Koeman, J.H., Brouwer, A. Interference of polychlorinated biphenyls in hepatic and brain thyroid hormone metabolism in fetal and neonatal rats. *Toxicol. and Appl. Pharmacol.* 1993;submitted.
- 4 Bastomsky, C.H. Effect of a polychlorinated biphenyl mixture (AROCLOR 1254) and DDT on biliary thyroxine excretion in rats. *Endocrinology* 1974;95:1150-1155.
- 5 Lans, M.C., Brouwer, A., Koppe, J.G. and van den Berg M. Enzyme induction and alterations in thyroid hormone, vitamin A and K levels by TCDD in neonatal and maternal rats. *Chemosphere* 1990;20(7-9):1129-1134.
- 6 Bastomsky, C.H. Enhanced thyroxine metabolism and high uptake goiters after a single dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Endocrinology* 1977;101:292-296.
- 7 Brouwer, A. Inhibition of thyroid hormone transport in plasma of rats by polychlorinated biphenyls. *Arch. Toxicol.* 1989;13:440-445.
- 8 Lans, M.C., Klasson-wehler, E., Willemsen, M., Meussen, E., Safe, S., Brouwer, A. Structure-dependent, competitive interaction of hydroxy-polychlorobiphenyls, -dibenzo-p-dioxins and -dibenzofurans with human transthyretin. *Chem.-Biol. Int.* 1993;submitted.
- 9 Lubet, R.A., Syp, J.-L., Nelson, J.O., Nims, R.W. Induction of hepatic cytochrome P-450 mediated alkoxyresorufin-O-deethylase activities in different species by prototype P-450 inducers. *Chem.-Biol. Int.* 1990;75:325-339.
- 10 Beetstra, J.B., Van Engelen, J.G.M., Karels, P., Van der Hoek, H.J., De Jong, M., Docter, R., Krenning, E.P., Henneman, G., Brouwer, A. and Visser, T.J. Thyroxine and 3,3',5-triiodothyronine are glucuronidated in rat liver by different uridine diphosphate-glucuronyltransferases. *Endocrinology*, 1991;128:741-746.
- 11 Klasson-Wehler, E., Kuroki, H., Athanasiadou, M. and Bergman, Å. Selective retention of hydroxylated PCBs in blood. In: *Organohalogen Compounds, Vol. 10, Toxicology, Epidemiology, Risk Assessment and Management*, Finnish Institute of Occupational Health, Helsinki 1992:121-122.
- 12 Van den Berg, M., personal communication.